Overview
TLX market data
Price History
TLX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- — Diluted earnings per share over the trailing twelve months.
- Beta
- — Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.28 – $14.27 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap —.
Company News
Telix H1 2026 Results: Investor Webcast NotificationGlobenewswire Inc · Jul 30, 2026, 11:15 PM
TLX591-Tx ProstACT SELECT Study Published in Cancers JournalGlobenewswire Inc · Jul 21, 2026, 10:00 PM
Telix Pharmaceuticals Announces Publication Of Results From The ProstACT SELECT Study In Cancers, A Peer-Reviewed Journal; Peer-Reviewed Publication of ProstACT SELECT1 Results Confirm The Utility Of 68Ga -PSMA-PET Imaging To Select Patients For TLX591-Tx Therapy Using A Theranostic ApproachBenzinga · Jul 21, 2026, 9:03 PM
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline ProgressGlobenewswire Inc · Jul 21, 2026, 11:00 AM
Reported Earlier, Telix FY2026 Revenue Guidance $950M-$970M Plus $40M Regeneron Payment, Total Expected Above $1BBenzinga · Jul 21, 2026, 6:43 AM
Reported Earlier, Telix Q2 Revenue $247M Up From $204M, With Precision Medicine Up 30% YoYBenzinga · Jul 21, 2026, 6:42 AM
Telix Pharmaceuticals Announces That The First Patient Has Been Dosed With TLX250-Tx In The LUTEON StudyBenzinga · Jul 20, 2026, 9:14 PM
Citigroup Maintains Buy on Telix Pharmaceuticals, Lowers Price Target to $22Benzinga · Jul 7, 2026, 6:30 PM
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price TargetBenzinga · Jul 7, 2026, 11:20 AM
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price TargetBenzinga · Jul 6, 2026, 12:50 PM